0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Effects of Protriptyline on Diurnal and Nocturnal Oxygenation in Patients with Chronic Obstructive Pulmonary Disease

Frédéric Sériès, MD; and Yvon Cormier, MD
[+] Article and Author Information

Grant Support: By La Fondation J. D. Bégin de l'Université Laval.

Requests for Reprints: Frédéric Sériès, MD, Centre de pneumologie, Hôpital Laval, 2725, chemin Ste-Foy, Quebec, Quebec, Canada GlV 4G5.

Current Author Addresses: Drs. Sériès and Cormier: Centre de pneumologie, Hôpital Laval, 2725, chemin Ste-Foy, Quebec, Quebec, Canada GlV 4G5.


©1990 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1990;113(7):507-511. doi:10.7326/0003-4819-113-7-507
Text Size: A A A

Objective: To determine the effects of a nonsedating tricyclic antidepressant (protriptyline) on pulmonary function (lung volume, expiratory flow), arterial blood gases, sleep architecture, and sleep-induced breathing abnormalities in patients with chronic obstructive pulmonary disease.

Design: A before-and-after trial in which patients, blinded to treatment, were given a placebo for 2 weeks, followed by 2 and 10 weeks of protriptyline treatment.

Setting: Referral-based pulmonology clinic in a public institution.

Patients: Sixteen outpatients were enrolled in the trial. Complete results for 11 patients and partial results for 3 patients are presented.

Interventions: Patients were evaluated at baseline, after receiving placebo for 2 weeks, and after 2 and 10 weeks of protriptyline therapy (20 mg/d, taken at bedtime).

Measurements and Main Results: At baseline, for the whole group, forced expiratory volume in 1 second (FEV1) was 1.0 ±0.08 L (mean ±SE); the partial pressure of O2 in arterial blood (PaO2) was 59 ±1.2 mm Hg; and the partial pressure of CO2 in arterial blood (Paco2) was 48.9 ±1.2 mm Hg. These variables remained stable after placebo. Pulmonary function test results were unchanged with protriptyline therapy. Arterial blood gas levels improved with such therapy: PaO2 levels increased by 5.1 ±1.4 mm Hg after 2 weeks and 6.7 ±2.4 mm Hg after 10 weeks (P < 0.01); PaCO2 levels decreased by 4.2 ±0.9 mm Hg after 2 weeks and 2.2 ±1.1 mm Hg after 10 weeks (P < 0.01). Total sleep times were similar at these visits. The only change in sleep architecture was a significant decrease in rapid eye movement (REM) sleep. The lowest value for the saturation of hemoglobin with O2 in arterial blood (SaO2) seen during sleep was 72.0% ±2.0% at baseline. After 2 and 10 weeks of protriptyline therapy, SaO2 values increased by 7.1% ±1.6% and 5.0% ±2.1%, respectively (P < 0.01). With protriptyline therapy, the cumulative SaO2 curve, derived from data obtained during sleep, shifted down and to the right.

Conclusions: Protriptyline improves diurnal and nocturnal hypoxemia in patients with chronic obstructive pulmonary disease. These changes are not related to changes in pulmonary mechanics.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)